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The CD95/CD95L- (Fas/FasL-) system is best known for
its capacity to induce cell death. However, recent data
indicate an additional role for Fas (CD95) in obviously
conflicting functions namely activation and proliferation.
We therefore investigated the effect of Fas co-ligation dur-
ing TCR/CD3/CD28-triggered activation of freshly iso-
lated human T-lymphocytes. We noted that plate-bound
but not soluble agonistic anti-Fas antibodies led to an
accelerated proliferation, suggesting a strong positive cos-
timulatory effect of Fas. Consistent with this observation,
more IL-2 and IFNg was produced and we observed
enhanced phosphorylation of STAT5, increased MAPK
and caspase activation and strong upregulation of activa-
tion markers and cell cycle proteins including CDKs and
cyclins. Also, as a consequence of ERK1/2 activation, the
phosphorylation of the Retino Blastoma Protein (Rb) at
serine 780 and 795 was more pronounced. Moreover,
activation-induced TCR internalization was enhanced
upon Fas-costimulation, allowing improved TCR translo-
cation and generation of signal platforms for optimal T
cell activation. Much to our surprise, ligation of Fas by
plate-bound but not soluble FasLFc fusion protein had an
opposite effect and blocked TCR-induced proliferation
almost completely. In this context, crucial events associ-
ated with T cell activation, i.e. tyrosine and ERK1/2 phos-
phorylation, expression of activation markers, IL-2
production and caspase activation were abrogated.
Although we do not have a clear explanation for the oppo-
site effects of the two types of ligation of the very same
receptor, we hope to find the answer in ongoing experi-
ments using a number of contructs that allow for differen-
tial oligomerziation or using FasL-transfectants to replace
the fusion proteins and monoclonal antibodies to estab-
lish a more physiological situation for primary T cell acti-
vation.
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